Abstract:Introduction Amyloid transthyretin amyloid cardiomyopathy (ATTR-CM) is a rare, systemic, life-threatening disease, characterized by both cardiac and extra-cardiac symptoms and signs. Its diagnosis remains challenging, however it is increasingly being pursued due to the availability of non-invasive diagnostic means, namely bone scintigraphy. Data regarding the prevalence of ATTR-CM in Greece are scarce. Purpose We aimed to study the prevalence and characteristics of ATTR-CM, both wild-type (ATTRwt-CM) and hereditary (ATTRv-CM), in patients with left ventricular hypertrophy (LVH) of undetermined etiology in Greece. Methods RETTRACE is an on-going, low- risk, prospective, multicenter, nationwide descriptive study, in 14 major outpatient Cardiology centers throughout Greece. Its primary endpoint is the prevalence of ATTR-CM in adults ≥ 50 years, with: a) Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and a left ventricular wall thickness (LVWT) of ≥12mm, or b) a LVWT ≥14 mm of unknown etiology. Secondary endpoints include the prevalence of ATTRv-CM, the description of clinical characteristics of ATTR-CM patients, and their quality of life, as evaluated with the Minnesota Living with Heart Failure Questionnaire (MLHFQ) and the EuroQol-5-Dimensions Questionnaire (EQ-5D-3L). Patients were screened and managed according to local clinical practice. Screening for light chain (AL) amyloidosis was done by immunofixation electrophoresis (serum and urine) and serum free light-chain (sFLC) assay, while biopsy was performed at the investigator's discretion. TTR genotyping was done centrally. Results The RETTRACE interim analysis (data-cut-off: May 31st, 2023), includes 153 patients (men: 52,9%), with a mean (SD) age of 77 (10.3) years. Basic demographics are shown in Table 1. Amongst patients who had bone scintigraphy results available, 71 (51.4%) were grade 0 according to the Perugini score. Furthermore, 62 tests of grades 1-3 were assessed by two independent reviewers and their final consensus was used to estimate the primary endpoint. In total, 24 out of 134 eligible patients were deemed to have ATTR-CM (17.9%), per applied criteria. Two of them carried mutations (Val114Ala and Ala101Thr respectively). As compared to non-ATTR-CM patients, those with ATTR-CM were older (mean age of 82.9 vs 76.0 years, p=0.004), less frequently hypertensive (54.2% vs 78.2%, p=0.021) and had more frequently undergone carpal tunnel surgery (29.2% vs 10.0%, p=0.021). Moreover, they had a poorer quality of life by MLHFQ (median 19.5 vs 40.0, p=0.05), while no significant differences were found in the EQ-5D-3L questionnaire. Conclusions ATTR-CM has a significant prevalence in a Greek population of adults ≥ 50 years with LVH of undetermined etiology. RETTRACE study results will provide valuable information for this underdiagnosed, life-threatening condition.

Suspected transthyretin cardiac amyloidosis by cardiac scintigraphy in heart failure with preserved ejection fraction, left ventricular hypertrophy and red flag manifestations

Prevalence of transthyretin cardiac amyloidosis in undifferentiated heart failure with preserved ejection fraction

A multicenter study of clinical predictors of positive pyrophosphate scintigraphy findings in the diagnosis of transthyretin amyloidosis

[Prevalence of transthyretin cardiac amyloidosis in patients hospitalized for heart failure with preserved ejection fraction and septal thickness]

Race, Sex, and Ejection Fraction-Based Differences in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Risk Prediction

Prevalence of transthyretin amyloid cardiomyopathy in patients admitted for acute heart failure

Myocardial Scintigraphy in Diagnosing Cardiac Transthyretin Amyloidosis

Prevalence of transthyretin amyloid cardiomyopathy in patients hospitalised for heart failure with preserved ejection fraction in an LATAM center

Diagnostic performance characteristics of planar quantitative and semi-quantitative parameters of Tc99m pyrophosphate (PYP) imaging for diagnosis of transthyretin (ATTR) cardiac amyloidosis: the SCAN-MP study

Trends in diagnosis of cardiac transthyretin amyloidosis: 3-year analysis of scintigraphic studies: Prevalence of myocardial uptake and its predictor factors

Prevalence of transthyretin amyloid cardiomyopathy in patients with left ventricular hypertrophy: the RETTRACE Study

99m Technetium-pyrophosphate scintigraphy: a practical guide for early diagnosis of transthyretin amyloid cardiomyopathy

Characteristics Of Negative And Equivocal Cardiac Scintigraphy Scans And Endomyocardial Biopsy Positive Transthyretin Cardiac Amyloidosis

The Association of Cardiac Biomarkers, the Intensity of Tc99 Pyrophosphate Uptake, and Survival in Patients Evaluated for Transthyretin Cardiac Amyloidosis in the Early Therapeutics Era

Prevalence of cardiac amyloidosis among elderly patients with recent-onset atrial fibrillation. The PREVAL-ATTR study.

Transthyretin cardiac amyloid: Broad heart failure phenotypic spectrum and implications for diagnosis

Transthyretin amyloid cardiomyopathy among patients with heart failure and preserved ejection fraction: the AMY score

First case of symptomatic transthyretin cardiac amyloidosis with rare Tyr78Phe variant, normal left ventricular wall thickness, and no cardiac uptake on scintigraphy

Prevalence and characteristics of transthyretin amyloid cardiomyopathy in hypertrophic cardiomyopathy

Usefulness of scintigraphy with [99mTc]Tc-DPD for the detection of transthyretin cardiac amyloidosis. Reference centre experience in an endemic area

Efficacy of Computed Tomography-Based Evaluation of Myocardial Extracellular Volume Combined With Red Flags for Early Screening of Concealed Cardiac Amyloidosis in Patients With Atrial Fibrillation